Please assess the completion status of the following clinical trial:

Trial Title: The Baroloop Study

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Aged 18 years or older and less than 80 years of age.~2. Persistent office systolic blood pressure (SBP) ≥ 140 mm Hg and diastolic blood pressure (DBP) \> 90 mm Hg on antihypertensive medicines on two visits separated by a minimum of four weeks.~3. Mean 24-hour systolic ABPM ≥ 130 mm Hg and mean 24 hour diastolic ABPM ≥ 80 mm Hg conducted after direct observed therapy to confirm that antihypertensive medicines were taken as prescribed during the ABPM measurement.~4. Stable drug regimen of 4 antihypertensive medicines consisting of a renin-angiotensin blocker(ACE) or Angiotensin II Receptor Blocker (ARBs), a calcium channel blocker (CCB), a diuretic and spironolactone for 4 weeks at treatment. If spironolactone is not tolerated, the regimen must include instead the addition of further diuretic therapy with either eplerenone, amiloride, higher-dose thiazide/thiazide-like diuretic or a loop diuretic, or the addition of bisoprolol or doxazosin. If none of these medicines are tolerated, then patients on a 3-drug regimen may be included.~5. The Investigator has confirmed that the patient has already tried and/or is not suitable for treatment with currently CE-marked device-based therapies for resistant hypertension as an alternative to baroloop therapy.~6. Willingness and ability to comply with follow-up requirements.~7. Signed informed consent.~Exclusion Criteria:~1. Any patient in whom access to the vagal nerve is limited by the size of the vagus (a size not compatible with the baroloop cuff).~2. Any patient with a history of injury to the vagus nerve or its branches (e.g., the recurrent laryngeal nerve).~3. Secondary causes of hypertension.~4. Calculated eGFR \< 30 mL/min/1.73m2.~5. Type 1 diabetes mellitus or poorly controlled type 2 diabetes mellitus (HbA1c \> 10%).~6. One or more episodes of orthostatic hypotension in the past year~7. Requirement for chronic oxygen therapy or mechanical ventilation.~8. Untreated (no CPAP therapy) sleep apnea (AHI \> 15)~9. Morbid obesity, defined as Body Mass Index \>40 kg/m2 or arm circumference 46 cm.~10. Pacemaker and/or implantable defibrillators.~11. History of transient ischemic accident or cerebrovascular accident during six (6) months prior to screening.~12. Symptomatic carotid artery disease or \> 70% occlusion of either carotid artery; any carotid malformation or lesion, a carotid bruit or other abnormal carotid sound.~13. Prior surgery, radiation therapy or scarring in the neck in the region of the carotid artery (e.g., patients with a tracheostomy, extensive thymectomy or thyroid surgery).~14. Limited mobility of the neck secondary to vertebral disease or prior vertebral surgery, including patients who wear a cervical support.~15. History of heart failure (NYHA class III-IV or ejection fraction \< 30%), myocardial infarction, unstable angina, coronary bypass or coronary angioplasty during six (6) months prior to screening.~16. Cardiac arrythmias (atrial fibrillation, atrial flutter, etc.) that require anticoagulation or interfere with a consistent measurement of blood pressure.~17. Syncope in the last 6 months.~18. History of bleeding disorders, thrombocytopenia, hemophilia or significant anemia (hemoglobin (Hgb) \< 10 gm/dl).~19. Current anticoagulation therapy (excluding antiplatelet therapy with aspirin as a sole therapy).~20. Works night shifts.~21. History of unresolved drug or alcohol use.~22. Active treatment of a psychiatric ailment.~23. Life expectancy of less than 12 months due to other disease.~24. Subject has a condition that, in the opinion of the investigator, precludes participation, including willingness to comply, with all follow-up procedures.~25. Participation in another clinical study for which follow-up is currently on-going.~26. Women who are of child-bearing age or who have the potential to become pregnant~27. Resting heart rate of \<40 beats/min for patients on beta blockers or \<60 beats/min for all other patients, confirmed at both baseline visits.~28. Baroreflex failure or autonomic neuropathy~29. Symptomatic, uncontrolled bradyarrhythmias~30. Atrioventricular block of any grade~31. Patients who are treated with Pacemaker and/or implantable defibrillators~32. Presence of a vagus stimulator~33. Patients who expect to require magnetic resonance imaging (MRI) of the cervical area~34. Occupational exposure to high levels of non-ionizing radiation that may interfere with therapy~35. Patients with a limited ability to read, understand and execute adjustment procedures (for example, persons suffering from dementia).~36. Likely exposure to diathermy.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Investigational Device (Type: EXPERIMENTAL): Subjects implanted with the baroloop device

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: terminate
termination_type: feasibility